{
    "clinical_study": {
        "@rank": "50364", 
        "arm_group": [
            {
                "arm_group_label": "Ampion < 5 kDa ultrafiltrate of 5% HSA", 
                "arm_group_type": "Experimental", 
                "description": "4 mL Intra-articular injection of Ampion"
            }, 
            {
                "arm_group_label": "Placebo solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "4 mL placebo intra-articular injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, placebo-controlled, double-blind study in which 500 patients with\n      osteoarthritis (OA) knee pain will be randomized to Ampion or placebo and followed for 20\n      weeks. The clinical effects of treatment on OA pain will be evaluated during clinic visits\n      at 6, 12, and 20 weeks using WOMAC\u00ae osteoarthritis Index and the Patient's Global Assessment\n      of disease severity (PGA). Safety will be assessed by recording adverse events, concomitant\n      medications, physical examination, vital signs and clinical laboratory tests."
        }, 
        "brief_title": "Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis of the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis and radiological evidence of symptomatic osteoarthritis of the\n             knee\n\n          -  Moderate to severe pain\n\n        Exclusion Criteria:\n\n          -  Other conditions in the knee, e.g., crystal arthropathies, septic necrosis, joint\n             replacement, major injury within 12 months prior to screening, tense effusions\n\n          -  Requires ongoing treatment with intra-articular pain medications or systemic\n             corticosteroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024529", 
            "org_study_id": "AP-004-A"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ampion < 5 kDa ultrafiltrate of 5% HSA", 
                "Placebo solution"
            ], 
            "description": "kDa ultrafiltrate of 5% human serum albumin", 
            "intervention_name": "Ampion", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "mcook@dreamteamclinic.com", 
                "last_name": "Michelle Cook", 
                "phone": "714-269-6161"
            }, 
            "facility": {
                "address": {
                    "city": "Anaheim", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92801"
                }, 
                "name": "Quang Vo, MD"
            }, 
            "investigator": {
                "last_name": "Quang Vo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of a Single Intra-articular Injection of AmpionTM (<5 Kilodalton Ultrafiltrate of 5% Human Serum Albumin) in Adults With Pain Due to Osteoarthritis (OA) of the Knee", 
        "overall_contact": {
            "email": "hloose@ampiopharma.com", 
            "last_name": "Holli Loose, MSc", 
            "phone": "720-437-6528"
        }, 
        "overall_official": {
            "affiliation": "Ampio Pharmaceuticals. Inc.", 
            "last_name": "Vaughan Clift, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement on WOMAC A Pain SubScore", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024529"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ampio Pharmaceuticals. Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ampio Pharmaceuticals. Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}